Barclays Initiates Coverage on SAB Biotherapeutics, Inc. (SABS) with Overweight
Rating Change Barclays analysts initiated coverage on SAB Biotherapeutics, Inc. (NASDAQ:SABS) with a Overweight rating on June 24, 2026. Market Context SAB Biotherapeutics, Inc.
Read more
